Close

Concordia International (CXRX) Under Heavy Pressure Amid Proposed UK Drug Price Bill

Go back to Concordia International (CXRX) Under Heavy Pressure Amid Proposed UK Drug Price Bill

RBC Capital Adds 'Speculative Risk' Qualifier to Concordia (CXRX) Rating, PT Cut to $14

September 19, 2016 8:37 AM EDT

RBC Capital analyst Douglas Miehm added a Speculative Risk qualifier to his Outperform rating on Concordia Healthcare (NASDAQ: CXRX) and lowered his price target to $14.00 (from $25.00).

Miehm commented, "The NHS tabled a bill late last week to further control UK medical... More

Canaccord Genuity Downgrades Concordia Healthcare (CXRX) to Spec. Buy

September 16, 2016 2:52 PM EDT

Canaccord Genuity downgraded Concordia Healthcare (NASDAQ: CXRX) from Buy to Spec. Buy with a price target of $10.00.

For an analyst ratings summary and ratings history on Concordia Healthcare click here. For more ratings news on Concordia Healthcare click here.

Shares of Concordia Healthcare closed at $6.61 yesterday.

... More

Concordia International (CXRX) Says It's Monitoring Health Service Medical Supplies (Costs) Bill

September 16, 2016 10:03 AM EDT

Concordia International Corp. (NASDAQ: CXRX today commented on the UK's Health Service Medical Supplies (Costs) Bill, which was introduced into the House of Commons on September 15, 2016. The proposed bill would amend and extend existing provisions of the National Health Service Act 2006 to help manage the cost of health service medicines.

"Concordia is supportive of... More